|Title:||Sialylated Immunoglobulins for the Treatment of Immuno-Inflammatory Diseases||Authors:||Markina, Yuliya V
Gerasimova, Elena V
Markin, Alexander M
Glanz, Victor Y
Sobenin, Igor A
Orekhov, Alexander N
|Keywords:||atherosclerosis; immuno-inflammatory diseases; immunoglobulins; inflammation; sialidase; sialylation||Issue Date:||31-Jul-2020||Publisher:||MDPI||Journal Volume:||21||Journal Issue:||15||Start page/Pages:||5472||Source:||International journal of molecular sciences||Abstract:||
Immunoglobulins are the potent effector proteins of the humoral immune response. In the course of evolution, immunoglobulins have formed extremely diverse types of molecular structures with antigen-recognizing, antigen-binding, and effector functions embedded in a single molecule. Polysaccharide moiety of immunoglobulins plays the essential role in immunoglobulin functioning. There is growing evidence that the carbohydrate composition of immunoglobulin-linked glycans, and especially their terminal sialic acid residues, provide a key effect on the effector functions of immunoglobulins. Possibly, sialylation of Fc glycan is a common mechanism of IgG anti-inflammatory action in vivo. Thus, the post-translational modification (glycosylation) of immunoglobulins opens up significant possibilities in the diagnosis of both immunological and inflammatory disorders and in their therapies. This review is focused on the analysis of glycosylation of immunoglobulins, which can be a promising addition to improve existing strategies for the diagnosis and treatment of various immuno-inflammatory diseases.
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.